24
Participants
Start Date
January 31, 2021
Primary Completion Date
October 21, 2023
Study Completion Date
November 3, 2023
Ondansetron 16 mg with Tariquidar
In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
Ondansetron 16 mg with Placebo
In randomized order, each participant will receive two IV infusions of ondansetron, 3 weeks apart; one with placebo (D5W), and one with tariquidar (4mg/kg dose in D5W) administered IV over 60 minutes. Ondansetron will be diluted in 100mL 0.9% normal saline, and tariquidar will be diluted in 500mL D5W.
Washington University School of Medicine/Barnes-Jewish Hospital, St Louis
Washington University School of Medicine
OTHER